ArticleWorld journal of gastrointestinal oncology2025
Cancer-associated fibroblasts, clinicopathological characteristics and prognosis of liver cancer: A systematic review and meta-analysis based on real-world research.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-associated fibroblasts (CAFs), crucial components of the tumor microenvironment in primary and metastatic tumors, can impact the activity of cancer cells and contribute to their progression. Given their extensive interactions with cancer cells and other stromal cells, we aimed to evaluate the prognostic value of CAFs in patients with liver cancer (LC).
aimTo investigate the association between CAF expression and clinicopathological characteristics as well as overall survival (OS) in patients with LC, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA).
methodsWe performed a meta-analysis of cohort studies with available data on the effects of CAF expression on both clinicopathological characteristics and OS
resultsNine trials were selected and included a total of 1518 patients. According to our primary meta-analysis, the expression of CAFs in LC patients was significantly associated with a decrease in OS (LC: HR: 1.62; 95%CI: 1.34-1.97;
conclusionHigh CAF expression, evaluated by both mixed markers and SMAs, is significantly associated with poor OS in patients with LC, including both HCC patients and iCCA patients. However, further research is necessary since how CAF expression and clinicopathologic features are related is yet unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.